Surgical Site Infections Pipeline | Companies- Destiny Pharma PLC, POLYPID, Exoxemis, Covira Surgical Inc., Eupraxia Pharmaceuticals, Sonoran Biosciences, and Others

DelveInsight, a leading market research and consulting firm, has recently published an in-depth report on the Surgical Site Infections pipeline, providing valuable insights into emerging therapies and companies.

 

DelveInsight’s, “Surgical Site Infection Pipeline Insight 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Surgical Site Infection pipeline landscape. It covers the Surgical Site Infection pipeline drug profiles, including Surgical Site Infection clinical trials and nonclinical stage products. It also covers the Surgical Site Infection therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the Surgical Site Infections Pipeline treatment landscape of the report, click here @ Surgical Site Infections Pipeline Outlook

 

Key Takeaways from the Surgical Site Infections Pipeline Report

• DelveInsight’s Surgical Site Infections Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Surgical Site Infections.
• The leading Surgical Site Infections Companies include Destiny Pharma PLC, POLYPID, Exoxemis, Covira Surgical Inc., Eupraxia Pharmaceuticals, Sonoran Biosciences, and Others.
• Promising Surgical Site Infections Pipeline Therapies include mupirocin calcium ointment, 3M Skin and Nasal Antiseptic, BACTROBAN® Nasal ong, Intranasal povidone-iodine, 70% v/v Isopropyl Alcohol Surgical Solution, Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic, ZuraPrep with 70% IPA, Ciprodiazole, gentamicin-collagen sponge dipped in saline, ertapenem sodium, D-PLEX, and others
• Surgical site infection typically appear 5 to 7 days post-procedure, however can develop up to 3 weeks after (especially if a prosthesis is inserted). The common clinical features of surgical site infections include: Spreading erythema; localized pain; Pus or discharge from the wound; and Persistent pyrexia.
• The Surgical site infection companies and academics that are working to assess challenges and seek opportunities that could influence Surgical Site Infection R&D. The Surgical site infection therapies under development are focused on novel approaches to treat/improve the disease condition.

 

For further information, refer to the detailed Surgical Site Infections Unmet Needs, Surgical Site Infections Market Drivers, and Surgical Site Infections Market Barriers, click here for Surgical Site Infections Ongoing Clinical Trial Analysis

 

Surgical Site Infections Overview

A surgical site infection is an infection that occurs after surgery in the part of the body where the surgery took place. Surgical site infections can sometimes be superficial infections involving the skin only. Other surgical site infections are more serious and can involve tissues under the skin, organs, or implanted material.

 

Request a sample and discover the recent advances in Surgical Site Infections Ongoing Clinical Trial Analysis and Medications, click here @ Surgical Site Infections Treatment Landscape

 

Surgical Site Infections Emerging Drugs Profile

 

• XF-73: Destiny Pharma plc

XF-73 is a synthetic dicationic porphyrin derivative with antibacterial activity. XF-73 has confirmed bactericidal activity. It is designated by the International Non-proprietary Name (INN) of exeporfinium chloride by the World Healthcare Organisation (WHO). XF-73 has been tested in vitro against a range of clinically important S. aureus isolates. It is active against methicillin-resistant S. aureus (MRSA), methicillin-sensitive S. aureus (MSSA), hospital associated-MRSA (HA-MRSA) and community-acquired MRSA (CA-MRSA), daptomycin resistant S. aureus, low- and high-level mupirocin-resistant S. aureus, linezolid-resistant MRSA and vancomycin-intermediate S. aureus (VISA).

 

• D-PLEX100: POLYPID

PLEX (Polymer-Lipid Encapsulation matriX) platform is made of alternating layers of polymers and lipids that entrap a therapeutic drug to form a protected reservoir. PLEX-based drug reservoirs enable prolonged delivery of unmodified drugs over periods ranging from days to several months, a rare combination of attributes. The novel D-PLEX100 product candidate delivers a broad-spectrum antibiotic, doxycycline, generating high local concentration over four weeks with minimal systemic exposure

 

Dive deep into rich insights for drugs for Surgical Site Infections Market Drivers and Surgical Site Infections Market Barriers, click here @ Surgical Site Infections Unmet Needs and Analyst Views

 

Surgical Site Infections Pipeline Therapeutics Assessment

There are approx. 5+ Surgical Site Infections companies which are developing the Surgical Site Infections therapies. The Surgical Site Infections companies which have their Surgical Site Infection drug candidates in the most advanced stage, i.e. phase III include, POLYPID.

 

Scope of the Surgical Site Infections Pipeline Report

• Coverage- Global
• Surgical Site Infections Companies- Destiny Pharma PLC, POLYPID, Exoxemis, Covira Surgical Inc., Eupraxia Pharmaceuticals, Sonoran Biosciences, and Others.
• Surgical Site Infections Pipeline Therapies - mupirocin calcium ointment, 3M Skin and Nasal Antiseptic, BACTROBAN® Nasal ong, Intranasal povidone-iodine, 70% v/v Isopropyl Alcohol Surgical Solution, Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic, ZuraPrep with 70% IPA, Ciprodiazole, gentamicin-collagen sponge dipped in saline, ertapenem sodium, D-PLEX, and others
• Surgical Site Infections Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Surgical Site Infections Mergers and acquisitions, Surgical Site Infections Licensing Activities @ Surgical Site Infections Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Executive Summary
3. Surgical Site Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Surgical Site Infection – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. D-PLEX100: POLYPID
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. XF-73: Destiny Pharma plc
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. F573: Beijing Continent Pharmaceutical
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. EP-201: Eupraxia Pharmaceuticals
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Surgical Site Infection Key Companies
21. Surgical Site Infection Key Products
22. Surgical Site Infection- Unmet Needs
23. Surgical Site Infection- Market Drivers and Barriers
24. Surgical Site Infection- Future Perspectives and Conclusion
25. Surgical Site Infection Analyst Views
26. Surgical Site Infection Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Er +/Her2 -Ve Breast Cancer Pipeline | Companies - BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and Others

DelveInsight, a leading market research and consulting firm, has recently published an in-depth report on the Er +/Her2 -Ve Breast Cancer Pipeline, providing valuable insights into emerging therapies and Companies.

 

DelveInsight’s, “ER+/ HER2-VE Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in ER+/ HER2-VE Breast Cancer pipeline landscape. It covers the ER+/ HER2-VE Breast Cancer pipeline drug profiles, including ER+/ HER2-VE Breast Cancer clinical trials and nonclinical stage products. It also covers the ER+/ HER2-VE Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the Er +/Her2 -Ve Breast Cancer Pipeline treatment landscape of the report, click here @ Er +/Her2 -Ve Breast Cancer Pipeline Outlook

 

Key Takeaways from the Er +/Her2 -Ve Breast Cancer Pipeline Report

• DelveInsight’s Er +/Her2 -Ve Breast Cancer Pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for Er +/Her2 -Ve Breast Cancer.
• The leading Er +/Her2 -Ve Breast Cancer Companies include BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others
• Promising Er +/Her2 -Ve Breast Cancer Pipeline Therapies include AZD9833, BGB-290, and others
• The Er +/Her2 -Ve Breast Cancer companies and academics are working to assess challenges and seek opportunities that could influence ER+/ HER2-VE Breast Cancer R&D. The Er +/Her2 -Ve Breast Cancer therapies under development are focused on novel approaches for ER+/ HER2-VE Breast Cancer.
• This segment of the ER+/ HER2-VE Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand Er +/Her2 -Ve Breast Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

For further information, refer to the detailed Er +/Her2 -Ve Breast Cancer Unmet Needs, Er +/Her2 -Ve Breast Cancer Market Drivers, and Er +/Her2 -Ve Breast Cancer Market Barriers, click here for Er +/Her2 -Ve Breast Cancer Ongoing Clinical Trial Analysis

 

Er +/Her2 -Ve Breast Cancer Overview

HR+ breast cancers are those that express estrogen receptors (ER) or progesterone receptors (PR) or both. These tumors account for 70–80% of all breast cancers. These hormone-dependent cancers can often be treated successfully with a variety of drugs that modulate ER or reduce estrogen.

 

Request a sample and discover the recent advances in Er +/Her2 -Ve Breast Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Er +/Her2 -Ve Breast Cancer Treatment Landscape

 

ER+/ HER2-VE Breast Cancer Emerging Drugs

 

• AZD9833: Astrazeneca

AZD-9833 acts as selective estrogen receptor degraders. It is being developed as combination therapy with palbociclib (a CDK4/6 inhibitor). It is currently in Phase III stage of dvelopement and is being developed by Astrazeneca.

 

• BGB-290: BeiGene

Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated for the treatment of HER2 Negative Breast Cancer. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene’s investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies. It is currently in Phase II stage of development for HER2-Negative Breast Cancer and is being developed by Beigene.

 

Dive deep into rich insights for drugs for Er +/Her2 -Ve Breast Cancer Market Drivers and Er +/Her2 -Ve Breast Cancer Market Barriers, click here @ Er +/Her2 -Ve Breast Cancer Unmet Needs and Analyst Views

 

Er +/Her2 -Ve Breast Cancer Pipeline Therapeutics Assessment

There are approx. 40+ Er +/Her2 -Ve Breast Cancer companies which are developing the ER+/ HER2-VE Breast Cancer. The Er +/Her2 -Ve Breast Cancer companies that have their ER+/ HER2-VE Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, AstraZeneca.

 

Scope of the Er +/Her2 -Ve Breast Cancer Pipeline Report

• Coverage- Global
• Er +/Her2 -Ve Breast Cancer Companies- BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others
• Er +/Her2 -Ve Breast Cancer Pipeline Therapies- AZD9833, BGB-290, and others.
• Er +/Her2 -Ve Breast Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Er +/Her2 -Ve Breast Cancer Mergers and acquisitions, Er +/Her2 -Ve Breast Cancer Licensing Activities @ Er +/Her2 -Ve Breast Cancer Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Executive Summary
3. Pipeline Therapeutics
4. Therapeutic Assessment
5. Late Stage Products (Phase III)
6. AZD9833: Astrazeneca
7. Drug profiles in the detailed report…..
8. Mid Stage Products (Phase II)
9. BGB-290: BeiGene
10. Drug profiles in the detailed report…..
11. Early Stage Products (Phase I/II)
12. OP-1250: Olema Pharmaceuticals
13. Drug profiles in the detailed report…..
14. Preclinical Stage Products
15. Drug Name: Company Name
16. Drug profiles in the detailed report…..
17. Inactive Products
18. ER+/ HER2-VE Breast Cancer Key Companies
19. ER+/ HER2-VE Breast Cancer Key Products
20. ER+/ HER2-VE Breast Cancer- Unmet Needs
21. ER+/ HER2-VE Breast Cancer- Market Drivers and Barriers
22. ER+/ HER2-VE Breast Cancer- Future Perspectives and Conclusion
23. ER+/ HER2-VE Breast Cancer Analyst Views
24. ER+/ HER2-VE Breast Cancer Key Companies
25. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Focal segmental Glomerulosclerosis Pipeline | Companies- Dimerix Bioscience, Travere Therapeutics, Horizon Therapeutics, Pfizer, Goldfinch Bio, Certa Therapeutics, ZyVersa Therapeutics, and Others

DelveInsight, a leading market research and consulting firm, has recently published an in-depth report on the Focal segmental Glomerulosclerosis Pipeline, providing valuable insights into emerging therapies, and companies

 

DelveInsight’s, “Focal Segmental Glomerulosclerosis Pipeline Insight 2023” report provides comprehensive insights about 15+ companies and 18+ pipeline drugs in the Focal Segmental Glomerulosclerosis pipeline landscape. It covers the Focal Segmental Glomerulosclerosis pipeline drug profiles, including Focal Segmental Glomerulosclerosis clinical trials and nonclinical stage products. It also covers the Focal Segmental Glomerulosclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the Focal segmental Glomerulosclerosis Pipeline treatment landscape of the report, click here @ Focal segmental Glomerulosclerosis Pipeline Outlook

 

Key Takeaways from the Focal SegmentalGlomerulosclerosis Pipeline Report

• DelveInsight’s Focal segmental Glomerulosclerosis Pipeline report depicts a robust space with 18+ active players working to develop 18+ pipeline therapies for Focal segmental Glomerulosclerosis.
• The leading Focal segmental Glomerulosclerosis Companies includes Dimerix Bioscience, Travere Therapeutics, Horizon Therapeutics, Pfizer, Goldfinch Bio, Certa Therapeutics, ZyVersa Therapeutics, Vertex Pharmaceuticals, Chinook Therapeutics, Delta 4, and others
• Promising Focal Segmental Glomerulosclerosis Pipeline Therapies include Acthar Gel, Dapagliflozin, DMX-200, Rituximab, and others
• FSGS with mutations in NPHS2 or TRPC6 is challenging to treat with immunosuppressive therapy; however, when such patients undergo kidney transplantation, the disease does not usually recur. APOL1 G1/G2 variants have been associated with a poor renal prognosis and steroid resistance in nephrotic syndrome/FSGS.
• The Focal segmental Glomerulosclerosis companies and academics are working to assess challenges and seek opportunities that could influence Focal Segmental Glomerulosclerosis R&D. The Focal segmental Glomerulosclerosis therapies under development are focused on novel approaches to treat/improve Focal Segmental Glomerulosclerosis.

 

For further information, refer to the detailed Focal segmental Glomerulosclerosis Unmet Needs, Focal segmental Glomerulosclerosis Market Drivers, and Focal segmental Glomerulosclerosis Market Barriers, click here for Focal segmental Glomerulosclerosis Ongoing Clinical Trial Analysis

 

Focal Segmental Glomerulosclerosis Overview

Focal Segmental Glomerulosclerosis (FSGS) is a major cause of idiopathic steroid-resistant nephrotic syndrome (SRNS) and end-stage kidney disease (ESKD). The pathogenesis of focal segmental glomerular sclerosis involves a complex interplay of several cell types, including podocytes, endothelial cells, and the basement membrane. Podocytes are terminally differentiated cells that provide structural support to the glomerulus and are essential in maintaining an intact glomerular filtration barrier, which is essential to prevent nephrotic range proteinuria.

 

Request a sample and discover the recent advances in Focal segmental Glomerulosclerosis Ongoing Clinical Trial Analysis and Medications, click here @ Focal segmental Glomerulosclerosis Treatment Landscape

 

Focal Segmental Glomerulosclerosis Emerging Drugs

• DMX-200: Dimerix Bioscience

DMX-200 is a chemokine receptor (CCR2) blocker and is administered to patients taking an angiotensin II type I (AT1) receptor blocker (ARB), which is the standard of care treatment for focal segmental glomerulosclerosis. DMX-200 has been granted patents in various territories until 2032 and has also been granted Orphan Drug Designation by the FDA and EMA. In 2020, DMX-200 demonstrated clear benefit to patients with FSGS in its first Phase IIa study in patients specifically with FSGS, following several successful studies in patients with a range of Chronic Kidney Diseases. All trial endpoints were achieved, and DMX-200 was determined to be safe and tolerable. DMX-200 is currently in a Phase III clinical trial for the treatment of FSGS.

• Sparsentan: Travere Therapeutics

Sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), is a novel investigational product candidate selectively targeting the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R). Pre-clinical data have shown that blockade of both endothelin type A and angiotensin II type 1 pathways in forms of rare chronic kidney disease reduces proteinuria, protects podocytes, and prevents glomerulosclerosis and mesangial cell proliferation. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted sparsentan orphan drug designation for FSGS. Currently, Sparsentan is in Phase III development for the treatment of focal segmental glomerulosclerosis (FSGS).

• Dazodalibep: Horizon Therapeutics

Dazodalibep is a CD40 ligand antagonist that blocks T cell interaction with CD40-expressing B cells, disrupting the overactivation of the CD40 ligand co-stimulatory pathway. Several autoimmune diseases are associated with the overactivation of this pathway. Horizon is also investigating dazodalibep in Sjögren’s Syndrome, Rheumatoid Arthritis and Kidney Transplant Rejection. Currently, Dazodalibep is in Phase II development for the treatment of focal segmental glomerulosclerosis (FSGS).

 

Dive deep into rich insights for drugs for Focal segmental Glomerulosclerosis Market Drivers and Focal segmental Glomerulosclerosis Market Barriers, click here @ Focal segmental Glomerulosclerosis Unmet Needs and Analyst Views

 

Focal Segmental Glomerulosclerosis Pipeline Therapeutics Assessment

There are approx. 15+ key companies which are developing the therapies for Focal Segmental Glomerulosclerosis. The companies which have their Focal Segmental Glomerulosclerosis drug candidates in the most advanced stage, i.e. phase III include, Dimerix Bioscience.

 

Scope of the Focal Segmental Glomerulosclerosis Pipeline Report

• Coverage- Global
• Focal Segmental Glomerulosclerosis Companies- Dimerix Bioscience, Travere Therapeutics, Horizon Therapeutics, Pfizer, Goldfinch Bio, Certa Therapeutics, ZyVersa Therapeutics, Vertex Pharmaceuticals, Chinook Therapeutics, Delta 4, and others
• Focal Segmental Glomerulosclerosis Pipeline Therapies- Acthar Gel, Dapagliflozin, DMX-200, Rituximab, and others
• Focal Segmental Glomerulosclerosis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Focal segmental Glomerulosclerosis Mergers and acquisitions, Focal segmental Glomerulosclerosis Licensing Activities @ Focal segmental Glomerulosclerosis Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Executive Summary
3. Focal Segmental Glomerulosclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Focal Segmental Glomerulosclerosis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. DMX-200: Dimerix Bioscience
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Dazodalibep: Horizon Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Focal Segmental Glomerulosclerosis- Unmet Needs
21. Focal Segmental Glomerulosclerosis- Market Drivers and Barriers
22. Appendix

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

United States Gluten Free Food Market, Size, Forecast 2023-2028

United States Gluten Free Food Market, Size, Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis

Renub Research has recently published a report titled "United States Gluten Free Food Market, Size, Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" providing a comprehensive analysis of the industry that includes market share insights. In addition, the report comprises competitor and regional research and contemporary extension. United States Gluten Free Food Market is projected to grow at 8.23% CAGR from 2023 to 2028. The surge in popularity of gluten-free diets in recent years has been remarkable, largely driven by a heightened awareness of gluten-related disorders. As a result, the market has witnessed a rapid expansion in the availability of gluten-free food options, catering to the needs of individuals adhering to such dietary restrictions.

 

Request a free sample copy of the report:  https://www.renub.com/us-gluten-free-food-market-p.php

 

In 2022, the United States gluten-free food industry alone was valued at an impressive US$ 2.56 Billion, reflecting the increasing demand for these products. The introduction and broader accessibility of gluten-free food have transformed what was once a challenging diet to follow into a more manageable and accessible lifestyle choice. While gluten-free diets have gained traction, it's important to note that gluten itself does not pose a significant health risk to the majority of the U.S. population. Less than 1% of individuals are affected by celiac disease, the most severe gluten-related disorder. Nonetheless, the demand for gluten-free foods remains high, driven by both medical necessity and dietary preferences of consumers across the United States.

 

However, it is worth mentioning that gluten-free foods sometimes face challenges in terms of nutrient deficiencies and taste and texture limitations. In the case of gluten-free bread, the typical replacement of wheat flour with refined flour and starches from alternative sources can result in certain drawbacks. For instance, incorporating dietary fiber, a crucial carbohydrate found in whole grains that offers important health benefits, into gluten-free bread can lead to a harder texture and more rapid staling, affecting the overall consumer experience.

 

An increasing number of Americans are embracing a health-conscious approach to their meals, prioritizing the avoidance of harmful substances and the pursuit of specific health benefits

 

The gluten free food market in the United States is undergoing a remarkable surge, driven by the bakery segment, which is playing a vital role in its growth.The United States gluten free food market is undergoing a remarkable surge, driven by the bakery, which is playing a vital role in its growth. The increasing demand for gluten-free products has spurred significant innovation within the bakery industry, resulting in a wide range of tantalizing gluten-free alternatives.

 

Gone are the days when individuals seeking gluten-free options had to sacrifice indulgent treats. Bakeries manufacturers have risen to the challenge, developing innovative recipes and techniques that deliver a diverse selection of delectable gluten-free baked goods items. These offerings cater not only to those with gluten-related disorders but also to individuals adopting gluten-free diets for various health and lifestyle reasons.

 

The bakery holds a substantial share in the thriving United States gluten free food market, contributing significantly to its overall value. This growth can be attributed to the escalating consumer awareness and demand for gluten-free options that do not compromise on taste, quality, or texture. To meet this demand, bakeries and confectionery companies are continually investing in research and development in United States.

 

Product Analysis have covered 8 Viewpoints in United States Gluten Free Food Market

 

1.    Bakery

2.    Dairy

3.    Meats

4.    Condiments

5.    Desserts

6.    Prepared meals

7.    Pasta & Rice

8.    Others

 

Supermarkets and hypermarkets play a dominant role in the United States gluten-free food market, providing consumers with convenient access to a wide array of gluten-free products and contributing to the industry's continued expansion

Supermarkets and hypermarkets hold a commanding position in the thriving gluten-free food market of the United States. These retail giants play a pivotal role in meeting the increasing consumer demand for gluten-free products by offering a diverse range of options. With their extensive shelf space and well-established distribution networks, supermarkets and hypermarkets ensure convenient accessibility and availability of gluten-free items to a wide customer base. Their contribution to the growth of the gluten-free food industry is substantial, as they continue to provide consumers with an extensive selection of gluten-free products while driving the expansion of the market as a whole.

 

Request a free sample copy of the report:  https://www.renub.com/request-sample-page.php?gturl=us-gluten-free-food-market-p.php

 

The efficiency and effectiveness of supermarkets and hypermarkets' distribution networks play a vital role in meeting the escalating demand for gluten-free products. These retail giants have developed well-established relationships with suppliers, enabling them to source gluten-free items efficiently and ensure a consistent supply for their customers. Their strong partnerships with suppliers also provide them with an advantage in negotiating favorable pricing, which in turn makes gluten-free options more accessible and affordable to consumers. By leveraging their distribution capabilities and supplier relationships, supermarkets and hypermarkets contribute to the wider availability and affordability of gluten-free products, catering to the needs of consumers seeking gluten-free dietary options.

 

Distribution channel Analysis have covered 9 Viewpoints in United States Gluten Free Food Market

 

1.    Convenience Stores

2.    Supermarket and Hypermarket

3.    Specialty Stores

4.    Online

5.    Drug Stores

6.    Club Stores

7.    Independent Natural

8.    Mass Merchandiser

9.    Others

 

Key Players

 

The United States gluten-free food market is a highly competitive landscape, characterized by the presence of both established players and emerging companies. Market leaders such as Conagra Brands, Inc., General Mills, The Hain Celestial Group, Kraft Heinz Company, Barilla G. e R. FratelliS.p.A, and Kellogg Co. hold significant market shares. These companies are actively investing in research and development (R&D) to enhance the flavor and quality of their gluten-free products, while also expanding their product portfolios.

 

All the Company Analysis have covered 3 Viewpoints in United States Gluten Free Food Market

 

1.    Overview

2.    Recent Developments

3.    Sales Analysis

 

Company Analysis

 

1.    Conagra Brands, Inc.

2.    General Mills

3.    The Hain Celestial Group

4.    Kraft Heinz Company

5.    Barilla G. e R. FratelliS.p.A

6.    Kellogg Co

 

About the Company:

 

Renub Research is a Market Research and Consulting Company. We have more than 14 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.

 

Contact Us:

Renub Research

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Email: info@renub.com

LinkedIn: https://in.linkedin.com/company/renub-research

Web: www.renub.com

Media Contact
Company Name: Renub Research
Contact Person: Rajat Gupta
Email:Send Email
Phone: +1-478-202-3244
Address:Roswell, GA 30076 http://www.renub.com/
City: Roswell
State: GA
Country: United States
Website: https://www.renub.com

India Hotel Market, Size, Forecast 2023-2030, Industry Trends

India Hotel Market, Size, Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis

Renub Research has recently published a report named "India Hotel Market, Size, Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" providing a detailed industry analysis that consists of market share insights. Furthermore, the report comprises competitor and regional research and contemporary extension in the India Hotel Market. India hotel market shall grow at a CAGR of 9.02% from 2022 to 2030. The tourism industry in India has witnessed a substantial rise in both domestic and international travel, encompassing leisure, business, and medical purposes. In February 2023, the number of Foreign Tourist Arrivals reached 865,779, showing a significant increase compared to 240,896 in February 2022. In addition, the expanding middle class and rising disposable incomes have increased travel and accommodation spending. 

 

Expert Insights: Ask Analyst or Download Full Report with TOC & Figures: https://www.renub.com/china-organic-food-market-p.php

 

 

The government's focus on infrastructure development, like improved transportation and connectivity, has made traveling to different parts of India more convenient. The Market Development Assistance (MDA) scheme guidelines update is to provide incentives to tourism stakeholders, broaden its scope and coverage, incorporate online promotions, and offer increased financial assistance. These revisions aim to improve the scheme's efficacy and provide more significant support to stakeholders promoting domestic tourism, maximizing their benefits. The development of hospitality services and the entry of international hotel chains have improved the quality and variety of accommodations available. Lastly, the promotion of popular tourist destination through marketing campaigns and initiatives has also contributed to the growth of the India hotel market.

 

 

New Delhi has hegemony in India Hotel Market

 

New Delhi is India capital city, attracting many tourists and business travellers due to its political, administrative, and cultural importance. Secondly, the town boasts a well-developed infrastructure with many hotels catering to different budget segments, from luxury accommodations to budget-friendly options. Thirdly, New Delhi is home to major international and domestic airports, making it easily accessible for domestic and international travellers. Additionally, the city is known for its historical landmarks, cultural attractions, and vibrant shopping and dining scenes, further boosting its appeal as a tourist destination. Lastly, New Delhi hosts numerous international conferences, exhibitions, and business events, driving the demand for hotel accommodations and supporting the growth of the hotel market in the city.

 

Request a free sample copy of the report:  https://www.renub.com/request-sample-page.php?gturl=india-hotel-market-p.php

 

Chandigarh growth in the hotel market can be due to its status as a significant economic and commercial hub, driving business travel. It is also a famous tourist destination for its urban design, gardens, and architectural landmarks, attracting domestic and international tourists. The city's infrastructural development, including an expanded airport and improved connectivity, has facilitated more accessible travel and contributed to hotel industry growth. Chandigarh's educational institutions, medical facilities, and government offices also attract students, patients, and officials who require accommodation. Its proximity to popular tourist destinations makes it a convenient stopover, supporting hotel market growth.

 

Cities – The India hotel market has been covered from 3 viewpoints:

 

1. 1.      Agra
2. 2.      Ahmedabad
3. 3.      Bengaluru
4. 4.      Chandigarh
5. 5.      Chennai
6. 6.      Goa
7. 7.      Gurugram
8. 8.      Hyderabad
9. 9.      Jaipur
10. 10.   Kochi
11. 11.   Kolkata
12. 12.   Mumbai
13. 13.   New Delhi
14. 14.   Pune
15. 15.   Udaipur
16. 16.   Other cities

 

Key Players.

 

ITC Hotels Limited, OYO, Lemon Tree Hotel, Treebo, Hyatt Hotels Corporation, InterContinental Hotel Groups, Marriott International, Radisson Blue Hotels, Shangri La Hotels & Resorts, Taj Hotels Resorts & Places, The Lalit Hotels, The Leela Palace, The Oberoi Group, The Park Hotels, Bharat Hotels Limited, Hotel Leelaventure Limited, The Indian Hotels Company Limited, Sarovar Hotels Private Limited, and Marriott Hotels India Private Limited are critical players in India hotel market.

 

Cities- India Hotel Market breakup from 3 Viewpoints:

1. Agra
2. Ahmedabad
3. Bengaluru
4. Chandigarh
5. Chennai
6. Goa
7. Gurugram
8. Hyderabad
9. Jaipur

10. Kochi

11. Kolkata

12. Mumbai

13. New Delhi

14. Pune

15. Udaipur

16. other cities

 

Indian Cities Hotel are Sub-divided into four parts

1. 1.    Number of Rooms
2. 2.    Room Average Daily Rate (ADR)
3. 3.    Revenue per Available Room (RevPAR)
4. 4.    Occupancy Rate

 

Type of Hotel - India Hotel Market

 

1. Luxury 
2. Upper Class
3. Middle Class
4. Economy

 

Star Rating - India Hotel Market

1. 1.    Five Star
2. 2.    Four Star
3. 3.    Three Star
4. 4.    Two Star

 

Origin Brand – India Hotel Market

 

1. 1.    Indian
2. 2.    International

 

Cities Tier - India Hotel Market

 

1. 1.    Tier-1
2. 2.    Tier-2
3. 3.    Tier-3

 

Booking Type - India Hotel Market

 

1. 1.    Hotel website
2. 2.    Aggregator
3. 3.    Self-booking/Walk-in Customer
4. 4.    Agent

 

Payment Mode – India Hotel Market

1. 1.    Credit card & Debit card
2. 2.    Net banking
3. 3.    UPI
4. 4.    Cash

 

Distribution by City

1. 1.   Existing Supply
2. 2.   Proposed Supply
3. 3.   Active Development of Supply

 

Administrative Region

1. 1.    North
2. 2.    West
3. 3.    East
4. 4.    South

 

Company has been covered from 3 Viewpoints:

 

1.   Overview 2.    Recent Development

3.    Revenue

 

Company Analysis:

 

1. ITC Hotels Limited
2. OYO
3. Lemon Tree Hotel
4. Treebo
5. Hyatt Hotels Corporation
6. InterContinental Hotel Groups
7. Marriott International
8. Radisson Blue Hotels
9. Shangri La Hotels & Resorts
10. Taj Hotels Resorts & Places
11. The Lalit Hotels
12. The Leela Palace
13. The Oberoi Group
14. The Park Hotels
15. Bharat Hotels Limited
16. Hotel Leelaventure Limited
17. The Indian Hotels Company Limited
18. Sarovar Hotels Private Limited
19. Marriott Hotels India Private Limited

 

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 14 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.

Media Contact
Company Name: Renub Research
Contact Person: Rajat Gupta
Email:Send Email
Phone: +1-478-202-3244
Address:Roswell, GA 30076 http://www.renub.com/
City: Roswell
State: GA
Country: United States
Website: https://www.renub.com

3D Semiconductor Packaging Market is expected to reach $8.7 Billion by 2028 - An exclusive market research report by Lucintel

Trends and Forecast for the 3D semiconductor packaging market

Trends, opportunities, and forecast for the global 3D semiconductor packaging market from 2017 to 2028 by technology (3D through silicon, 3D package on package, 3D fan out , 3D wire bonded, and others), material (organic substrates, bonding wires, lead frames, encapsulation resin, ceramic package, die attach materials, and others), end use industry (consumer electronics, industrial, automotive, healthcare, IT & telecommunication, aerospace & defense, and others),

Lucintel's latest market report analyzed that 3D semiconductor packaging provides attractive opportunities in the consumer electronic, industrial, automotive, healthcare, IT & telecommunication, and aerospace & defense industries. The 3D semiconductor packaging market is expected to reach $8.7 billion by 2028 with a CAGR of 19%. In this market, 3D through silicon is the largest segment by technology, whereas consumer electronics is largest by end use industry.

Based on technology, the 3D semiconductor packaging market is segmented into 3D through silicon, 3D package on package, 3D fan out, 3D wire bonded, and others. The 3D through silicon segment accounted for the largest share of the market in 2023 and is expected to register the highest CAGR during the forecast period, due to its high density and short connection; hence, it is preferred over package-on-package.

Browse in-depth TOC on “3D Semiconductor Packaging Market”

100 – Figures/Tables

150 – Pages

The 3D Semiconductor Packaging Market is marked by the presence of several big and small players. Some of the prominent players offering 3D semiconductor packaging include Amkor Technology, ASE group, Siliconware Precision Industries, Jiangsu Changjiang Consumer, and SSS MicroTec AG.

Request Sample Report: https://www.lucintel.com/3d-semiconductor-packaging-market.aspx

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link helpdesk@lucintel.com.

About Lucintel

Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.

Roy AlmaguerLucintel Dallas, Texas, USA Email: roy.almaguer@lucintel.com  Tel. 972.636.5056

Media Contact
Company Name: Lucintel
Contact Person: Roy Almaguer
Email:Send Email
Phone: 972.636.5056
Address:8951 Cypress Waters Blvd., Suite 160
City: Dallas
State: TEXAS
Country: United States
Website: https://www.lucintel.com/

Transform Style In Seconds: Elfin Hair 100% Glueless Wear & Go Wigs

Renowned for being at the cutting edge of wig trends, Elfin Hair proudly announces the release of their innovative wear & go wigs. As a reliable online hair store that has earned a great number of positive reviews, Elfin Hair continues to uphold its commitment to providing the best human hair wigs for black women at affordable prices. With this new collection, they set a fresh industry standard for ease, convenience, and style. These wear & go wigs are genuine glueless lace wigs, designed for quick and easy application within seconds. Even if you go clubbing, these wigs stay securely in place, ensuring you never miss a beat.

Pre-Cut HD Lace: The glueless lace wig collection, titled "Wear And Go," has been thoughtfully designed with user-friendliness at its core. It features pre-cut HD lace, saving time for customers to cut extra lace themselves. The natural, pre-plucked hairline enhances the seamless blend of the wig, creating a look so flawless it's virtually undetectable. 

Beginners Friendly: The wear and go glueless wigs are a game-changer for beginners. With pre-bleached knots and a simple installation process that takes as little as 30 seconds, these wigs require no previous experience or professional skills. These wear & go wigs are genuine glueless lace wigs, designed for quick and easy application within seconds. Whether you're heading out for a night on the town or hitting the club, these wigs stay securely in place, ensuring you never miss a beat.

Real Glueless Lace Wig: The true innovation lies in the glueless design. With no glue or gel necessary, these wigs incorporate a non-slip silicone strip and an adjustable elastic band, ensuring a perfect fit. 

3D New Breathable Cap: The 3D New Breathable Cap is another groundbreaking addition, expertly crafted to fit comfortably while allowing the scalp to breathe. 

100% Human Hair: Every wig in the collection boasts 100% raw human hair, known for its soft and bouncy texture. These wigs can be dyed or flat ironed without causing any damage, ensuring versatility and longevity.

 

These wear and go wigs are more than just a product—they're a testament to Elfin Hair's continuous innovation in the wig industry. Their dedication to providing high-quality, affordable human hair wigs remains their driving force. When you choose one of these wigs, you're not just picking a new hairstyle - you're embracing a powerful expression of your unique self and sparking a splendid transformation.

To experience this revolutionary wear & go wig collection, visit Elfin Hair today. Stay connected with the latest from Elfin Hair on:

Facebook: https://www.facebook.com/elfinhair 

Instagram: https://www.instagram.com/elfinhair/ 

Youtube: https://www.youtube.com/user/elfinhair 

Pinterest: https://www.pinterest.com/elfinhair/

About Elfin Hair:

Elfin Hair has been a trusted brand in the wig industry for years, continually delivering high-quality, trend-setting human hair wigs for black women. Their passion lies in providing superior human hair wigs and human hair extensions at accessible prices. They are steadfast in their mission to offer cost-effective human hair wigs, making it possible for every black woman to confidently express her style, charm, and self-assuredness!

For more information on the Wear & Go Wig Collection, please visit elfinhair.com

Media Contact
Company Name: ELFIN HAIR
Contact Person: AILSA
Email:Send Email
Phone: +86-15013223107
Country: China
Website: https://www.elfinhair.com/

Correction: Master Class Speaker Harrison Klein to Speak at Upcoming I Am Greater Summit Retreat 2023

Join world-renowned transformational leader Harrison Klein at the I Am Greater Summit Retreat. Experience his powerful master class and gain practical tools for personal and professional growth. Register now!

Sunrise, FL - Write Choice Consulting Firm is thrilled to announce that Harrison Klein, a world-renowned transformational leader, author, and international award-winning speaker, will be speaking at the upcoming I Am Greater Summit Retreat. The retreat, titled "Come Great, Leave Greater!", will be held from October 1-5, 2023, at the luxurious Hacienda Del Mar Los Cabos Resort.

Harrison Klein is an internationally recognized expert in personal and professional development, having trained and coached thousands of individuals worldwide. As a pioneer in the Telesummit industry, the author of several acclaimed books, including “Spiritual Wealth”, “Body Wisdom”, and “Sustained Focus" he has been a featured guest on over 100 radio and TV programs worldwide and garnered attention from prestigious major media outlets such as ABC and NBC News and over 40 other broadcast shows around the world.

At the I Am Greater Summit Retreat; Mr. Klein will deliver a powerful master class presentation on transformation, environment and enlightened leadership that will inspire and empower attendees. His extensive experience and expertise will provide practical knowledge and tools to help participants achieve their personal and professional goals.

"We are honored to have Harrison Klein as a master class speaker at this year's retreat," said Telena Paris, CEO at Write Choice Consulting Firm. "His insights and strategies have positively impacted countless individuals worldwide, guiding them towards achieving their goals and living fulfilling lives. We are confident that his master class will be a highlight of the retreat."

The I Am Greater Summit Retreat promises to be an unforgettable and rejuvenating experience for attendees. In addition to Harrison Klein's master class, the retreat offers a range of activities designed to help participants connect with nature and find balance in their lives. From exploring the underwater world of Los Cabos to rock climbing, extreme sports activities, golfing, hiking to the waterfalls at Santiago, or indulging in a relaxing spa day, attendees will have ample opportunities for personal growth and enjoyment.

The retreat will also feature appearances and engagements with other renowned speakers and influencers, including Jeffrey Hayzlett, Jeremy Tillman, Vanessa McBee, Nikki Oxley, Sir Dr. James Dentley III, Dame Dr. Kara Scott-Dentley, Debra Poneman, Kiamesha Wilson, Felisha Monet, and many more.

Additionally, the I Am Greater Summit Retreat is proud to welcome the Wealthy Mofos Million Dollar Coach program as a strategic partner. This program offers the ultimate coaching experience for coaches, speakers, and entrepreneurs who are seeking to elevate their businesses to the next level. With a proven track record of success and a team of multi-million-dollar industry experts, the Million Dollar Coach program provides personalized coaching, strategic planning, and cutting-edge tools to help participants achieve their business goals. Whether you are just starting out or looking to scale up, the program equips you with everything you need to succeed.

"We are excited to have the Wealthy Mofos Million Dollar Coach program as part of the I Am Greater Summit Retreat," said Telena Paris. "Their expertise and commitment to empowering coaches, speakers, and entrepreneurs align perfectly with our mission to facilitate personal and professional growth. Attendees will have the opportunity to gain invaluable insights from this prestigious program."For more information about the I Am Greater Summit Retreat, including Harrison Klein's master class and the Wealthy Mofos Million Dollar Coach program, and to register for the event, please visit www.iagreater.com.

About Write Choice Consulting Firm:

Write Choice Consulting Firm is a certified SBE & CBE minority woman-owned international organizational & grant/fund development consulting firm and professional development learning institute. The firm provides high-quality advisory and organizational support services to non-profit and for-profit organizations, with a particular focus on small and medium-sized businesses worldwide. Their services encompass a wide range of advisory and support offerings, assisting organizations in achieving their goals and fostering growth.

"We are dedicated to providing a range of high-quality advisory and support services to organizations, both non-profit and for-profit, to help them thrive and succeed," added Telena Paris. "At Write Choice Consulting Firm, we believe in the power of personal and professional development, and we are committed to empowering individuals and businesses to reach their full potential."

The I Am Greater Summit Retreat, organized by Write Choice Consulting Firm, is an exceptional opportunity for attendees to engage with renowned experts like Harrison Klein and the Wealthy Mofos Million Dollar Coach program. By attending the retreat, participants will gain valuable insights, practical tools, and connections with like-minded individuals, all aimed at driving their personal and professional growth.

To learn more about the I Am Greater Summit Retreat and to register for the event, please visit the official website at www.iagreater.com.

For additional information about Write Choice Consulting Firm and their range of advisory services, please visit www.writechoiceconsult.org.

Contact: Charity Christensen, Marketing Specialist, Write Choice Consulting Firm, Phone: 877-844-GREAT (7328) Email: cchristensen@writechoiceconsult.org

Media Contact
Company Name: Write Choice Consulting Firm
Contact Person: Charity Christensen
Email:Send Email
Phone: 8778447328
Address:1560 Sawgrass Corporate Parkway 4th Floor
City: Sunrise
State: Florida
Country: United States
Website: www.iagreater.com/

New book "God is Proven" by David Steineker is released, a unique exploration of scripture and science that reframes the nature of truth and prepares readers for judgment

“God is Proven” by David Steineker has been released worldwide. This 267-page work is a deep dive into misinterpretations that claim to understand truth, purpose, and judgment, providing a new perspective on the creation of the universe, the meaning of life, and the importance of love as a form of worship. 

Examining scripture, science, and human behaviors across time, Steineker uses metaphor, mathematics, and key Biblical passages to explain long-held beliefs in a new light. He shows that common interpretations of Genesis 1:1 are critically mistaken in separating God and Creation, and that such interpretations have led people to glorify work. This focus on works over truth and love has led people astray, causing them to unwittingly betray God’s purpose by seeking the approval and praise of Man. 

This book builds on the author’s previous work, The Greatest Commandment, and takes an interdisciplinary approach to exposing the human arrogance that has pulled people away from truth, the sin of self-deception, and the challenges that await the deceived at judgment. 

Among numerous other topics, The author outlines the fascinating paradox of infinite time, an infinite God, and the conflicting wording between Genesis 1:1 and John 3:16. He explores the stories of Abraham, Noah, Job, and beyond, as well as the history of chemistry, the message of Jesus, and the interwoven relationship among truth, love, divinity, and becoming a child of God. 

Drawing from many cited sources, scripture, and a background as a chemistry teacher, Steineker presents a thought-provoking, multifaceted view of the universe itself. With a detailed list of references and a reading group guide, he also prompts further discussion and deeper understanding of these ideas. This book covers broad ground, and connects each concept back to a central theme: God’s message of love is only comprehensible to those who accept the truth.

God is Proven (ISBN: 9781960142238) can be purchased through retailers worldwide, including Barnes and Noble and Amazon. The paperback retails for $18.99, the hardcover retails for $24.99, and the ebook retails for $9.99. Wholesale orders are available through Ingram. Review copies and interviews are available upon request.  

From the back cover:

God is Proven comes before Emmanuel. Genesis 1:1 promotes the Creator as being separate from Creation. Emmanuel does not mean Creation is with us. Jesus had to prove he is God. Jesus declared he is God when he said I am the truth. A God is a truth origin. Emmanuel means Creator is with us and that is in direct contradiction to Genesis 1:1. Nowhere in Genesis 1:1 does it mention Jesus being with the Creator and the reason today the Jews and Muslims do not accept Emmanuel. Even though God is Proven, it is still a belief for us because we are not a truth origin. If you are not a truth origin, then you must believe in the truth origin because it is not your own. All truth requires evidence and boundaries, otherwise it would change, so this book provides evidence for you to get prepared for judgment.

About the author:

David T. Steineker served in the U.S. Army as an 11c and received an Honorable Discharge. He is a University of Louisville graduate, awarded United States Patent No.: US 7,910,358 B1, founder of National Periodic Table Day, and has taught Chemistry for 27 years. He and Allison, his wife, live in Kentucky, with their four children. 

About MindStir Media:

MindStir Media LLC is an award-winning book publisher. To learn more about publishing a book with MindStir Media, visit http://mindstirmedia.com or call 800-767-0531.

Media Contact
Company Name: MindStir Media LLC
Contact Person: Jen McNabney
Email:Send Email
Phone: 800-767-0531
Address:1 New Hampshire Ave Suite 125
City: Portsmouth
State: NH
Country: United States
Website: https://mindstirmedia.com/

Introducing Dēp Slēpwear: A revolutionary sleep hoodie designed to optimize sleep quality

Discover the transformational potential of Dēp Slēpwear and unlock a new level of sleep quality.

Dēp Slēpwear has officially launched its patented Dēp Sleep Hoodie and is on a mission to help the millions of people struggling with sleep challenges achieve faster, deeper, and longer sleep. This ground-breaking sleepwear combines comfort with the three factors necessary for restful sleep: darkness, quiet, and body temperature regulation. The Dēp Sleep Hoodie transforms how we sleep by creating the optimum sleeping environment, whether at home or on the go. A clever and comfortable built-in sleep mask in the Dēp Sleep Hoodie effectively blocks light to encourage deeper, more peaceful sleep. The mask also covers the ears to muffle outside noise and create a tranquil private sleep cocoon. And the sweat-wicking fabrics in the hoodie help control body temperature, providing cool and comfortable sleep all night long. 

Popular among people with insomnia and other sleep challenges, the Dēp Slēpwear Hoodie has also been embraced by professional athletes and coaches in all major U.S. sports leagues, including the NBA, NHL, NFL, MLB, MLS, and beyond. The Dēp Slēpwear solution has also earned endorsements from prominent sleep specialists, sleep coaches, performance coaches, and military veterans. 

Dēp Slēpwear was created by founder and CEO Glenn Paradise to help him deal with his own issues with insomnia. "It certainly helps me sleep better. And it’s a great feeling when customers tell me they are experiencing an additional 30 minutes of deep sleep some nights," he said. Deep sleep is the phase of sleep when muscles build and repair, making it especially important for athletes who are always searching for ways to improve recovery and performance. When wearing the Dēp Slēpwear Hoodie, Paradise continued, customers frequently report better sleep scores from their sleep trackers, like Oura and Whoop. 

Dēp Slēpwear has rapidly risen to fame globally since its inception in 2018. In 2019, the Indiana Pacers was the first NBA team to use this ground-breaking sleepwear. Since then, Dēp Slēpwear has earned the trust of athletes, teams, and recovering insomniacs in more than 20 nations. Recognizing the Dēp Sleep Hoodie's potential to improve sleep quality, renowned sleep expert Dr. Michael Breus, better known as The Sleep Doctor, also supports it. He says, "Dēp Slēpwear is one of my favorite moisture-wicking pajamas. They can help you stay cool, dry, and comfortable all night long.” Dēp Slēpwear is also a godsend for frequent travelers as it can help prevent the dreaded "first night effect" and guarantees sound sleep throughout long flights and bus rides. 

To learn more visit: https://depslepwear.com

About Dēp Sleepwear

In 2018, Dēp Slēpwear was established to revolutionize how people sleep. Pro athletes and sleep experts alike support the unique Dēp Sleep Hoodie, which blends darkness, quiet, and body temperature management to produce an ideal sleeping environment. Dēp Slēpwear, which has clients in more than 20 nations, is redefining sleep hygiene worldwide.

Media Contact
Company Name: Dep Slepwear
Contact Person: Glenn Paradise
Email:Send Email
City: Boston
State: Massachusetts
Country: United States
Website: www.depslepwear.com

Unraveling the Power of Words: A Journey from Destruction to Divine Healing in Sherita Charmaze White's 'Broken by Man’s Words, Healed by God’s Words'

Jacques Derrida, the famous French Philosopher talks about the deconstruction of language in his theory of deconstruction. His philosophy claimed that language – any language – is unstable and ambiguous. This means that anything can have multiple meanings, perceptions, conflicts, and so on. Later, many other philosophers agreed and unanimously decided that language is manmade.

But what it is that this manmade aspect of nature, can make or break a person. There is something lacking in the human senses transfer that they needed to create oral communication. While the philosophy is a never-ending discussion, it is absolutely agreed upon that language, in fact, does have comforting and destructive elements.

Sherita Charmaze White deals with the power of words – especially words of the divine – in her book Broken by Man’s Words, Healed by God’s Words. White begins the book just as this article was begun. With the understanding and power of the word. However, earlier in the chapter, she established that this book serves to help a man be closer to God by understanding His words.

It is important to mention that White also establishes the fact that words do directly associate with the emotion of perceiving. She indirectly talks about words and how they can hurt when you are expecting another emotion to flow from the other person. For example, it may hurt more to hear someone you love to belittle you. Similarly, people may be proud of you all the time, but it brings special happiness when one’s parents say a few simple words showing pride.

Along with several other biblical references, White seems to nail it initially when she used the following verse. “In the beginning was the Word, and the Word was with God, and the Word was God.” This helps her eventually prove people wrong who she has mentioned have told her that ‘words don’t matter.’

Keeping the idea of perceiving words to accomplish an emotion, White subtly expresses the idea that maybe we don’t see God as a friend anymore or a guide. Finding a friendly and valuable relationship with God is the first step you can take. This step will help YOU find peace in life and not get hit with the power of negative words in the world.

One of the best parts of this self-help/self-reflection book is that it helps practice than just preach. Throughout the book, you will see that every topic deals with a morally positive approach and the proof of the teachings are quoted in God’s words.  Each of the sections in the book helps teaches to let people know that God is not only about worshipping him. He is very much so inclined to teach positive morals so that none of His children suffer on the planet.

This non-fiction book serves as a journal too so you can experiment with your inner self and actually learn what you read and implement it.

Just as White talks about the types and effects of positive words, she also dives deep into the different types of negative words. Some of them we don’t even realize how we have incorporated them into our lives and have subconsciously become the villain of other people’s lives.

Perhaps the most interesting part to read was how words are used for manipulation. Man is a target of being manipulated since the beginning of time. In fact, negative words that brought out enticement were the reason for the fall of man. White smartly and beautifully quotes Genesis to recall this incident. She talks about how not only humans, but other creatures can also manipulate words too.

The serpent did not have to do much other than get the words here and there to find a sense of trust and spark a factor of curiosity that ultimately led to man’s doom.

Apart from talking about the different types of words that make a difference in a person’s life, White talks about God’s solution to it. She drastically mentions how different approaches can make the sender and the receiver both on the right path.

Another very relatable aspect that is talked about in well-depth in this book is the case of anger. Anger changes a person and seems to render senses unable to perform. Anger listens to something never said and speaks of what should not have been spoken! Truly the enemy of man! White talks about situations such as anger and talks about how to replace them with God’s words so that ample reactions can be given out.

She beautifully portrays the idea of venting out. Venting out is one of the most accepted notations in psychology. However, White tells her readers the right ways to vent out to God. It almost feels like we can say anything to God, and White has a pretty good reason to convince us to:

“I don’t know about you, but I would rather the Lord be angry with me than have other people angry with me. Why? The Lord has more grace and mercy than some people, even when He’s angry.”

Similar to this, there are several examples in Broken by Man's Words and Healed by God's Words. It serves as a philosophical exploration of the transformative power of words and the healing potential found within God's divine message. Throughout the book, White dives into the various forms and impacts of human words, revealing how they can inflict pain, cause brokenness, and leave lasting wounds on our hearts and souls.

The one hope that lies amidst the wreckage caused by the destructive nature of human communication is God's words. These possess healing capabilities.

The writer authentically illustrates how God's teachings, scriptures, and divine guidance have the remarkable ability to mend our shattered spirits, mend broken relationships, and restore our sense of purpose and meaning.

Overall, this book urges readers to turn to the divine source of wisdom and guidance, recognizing that it is through the embrace of God's words we find restoration.

Media Contact
Company Name: Book Name: Broken by Man's Words, Healed by God's Words
Contact Person: Author Name: Sherita C. White
Email:Send Email
Country: United States
Website: https://www.amazon.com/Broken-Mans-Words-Healed-Gods/dp/1955297266/